LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Lapatinib | 0.37 | uM | LJP6 | 3 | M22 | 72 | hr | 1476 | 1596 | 3694 | 0.4321 | 0.0538 |
| SK-BR-3 | LDN-193189 | 0.37 | uM | LJP5 | 1 | G04 | 72 | hr | 1476 | 4097 | 3694 | 1.1091 | 1.1817 |
| SK-BR-3 | LDN-193189 | 0.37 | uM | LJP5 | 2 | G04 | 72 | hr | 1476 | 4210 | 3694 | 1.1397 | 1.2327 |
| SK-BR-3 | LDN-193189 | 0.37 | uM | LJP5 | 3 | G04 | 72 | hr | 1476 | 4240 | 3694 | 1.1478 | 1.2462 |
| SK-BR-3 | Linifanib | 0.37 | uM | LJP6 | 1 | J10 | 72 | hr | 1476 | 3502 | 3694 | 0.9480 | 0.9134 |
| SK-BR-3 | Linifanib | 0.37 | uM | LJP6 | 2 | J10 | 72 | hr | 1476 | 4144 | 3694 | 1.1218 | 1.2029 |
| SK-BR-3 | Linifanib | 0.37 | uM | LJP6 | 3 | J10 | 72 | hr | 1476 | 4166 | 3694 | 1.1278 | 1.2128 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 1 | O22 | 72 | hr | 1476 | 3053 | 3694 | 0.8265 | 0.7109 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 2 | O22 | 72 | hr | 1476 | 3053 | 3694 | 0.8265 | 0.7109 |
| SK-BR-3 | Linsitinib | 0.37 | uM | LJP5 | 3 | O22 | 72 | hr | 1476 | 3191 | 3694 | 0.8638 | 0.7731 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP5 | 1 | C22 | 72 | hr | 1476 | 1631 | 3694 | 0.4415 | 0.0696 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP5 | 2 | C22 | 72 | hr | 1476 | 1630 | 3694 | 0.4413 | 0.0691 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP5 | 3 | C22 | 72 | hr | 1476 | 1548 | 3694 | 0.4191 | 0.0321 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP6 | 1 | C22 | 72 | hr | 1476 | 1431 | 3694 | 0.3874 | -0.0206 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP6 | 2 | C22 | 72 | hr | 1476 | 1697 | 3694 | 0.4594 | 0.0993 |
| SK-BR-3 | Mitoxantrone | 0.37 | uM | LJP6 | 3 | C22 | 72 | hr | 1476 | 1541 | 3694 | 0.4172 | 0.0290 |
| SK-BR-3 | MK2206 | 0.37 | uM | LJP6 | 1 | F04 | 72 | hr | 1476 | 2518 | 3694 | 0.6816 | 0.4696 |
| SK-BR-3 | MK2206 | 0.37 | uM | LJP6 | 2 | F04 | 72 | hr | 1476 | 2522 | 3694 | 0.6827 | 0.4714 |
| SK-BR-3 | MK2206 | 0.37 | uM | LJP6 | 3 | F04 | 72 | hr | 1476 | 2632 | 3694 | 0.7125 | 0.5210 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 1 | A16 | 72 | hr | 1476 | 1432 | 3694 | 0.3877 | -0.0202 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 2 | A16 | 72 | hr | 1476 | 1346 | 3694 | 0.3644 | -0.0590 |
| SK-BR-3 | Neratinib | 0.37 | uM | LJP5 | 3 | A16 | 72 | hr | 1476 | 1243 | 3694 | 0.3365 | -0.1054 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 1 | N16 | 72 | hr | 1476 | 4041 | 3694 | 1.0939 | 1.1565 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 2 | N16 | 72 | hr | 1476 | 4034 | 3694 | 1.0920 | 1.1533 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 3 | N16 | 72 | hr | 1476 | 4187 | 3694 | 1.1334 | 1.2223 |